Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates.

Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, King AR, Redhi GH, Yasar S, Piomelli D, Goldberg SR.

Biol Psychiatry. 2008 Dec 1;64(11):930-7. doi: 10.1016/j.biopsych.2008.08.008. Epub 2008 Sep 23.

2.

Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys.

Schindler CW, Scherma M, Redhi GH, Vadivel SK, Makriyannis A, Goldberg SR, Justinova Z.

Psychopharmacology (Berl). 2016 May;233(10):1867-77. doi: 10.1007/s00213-016-4211-3. Epub 2016 Jan 23.

3.

Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat.

Cippitelli A, Cannella N, Braconi S, Duranti A, Tontini A, Bilbao A, Defonseca FR, Piomelli D, Ciccocioppo R.

Psychopharmacology (Berl). 2008 Jul;198(4):449-60. doi: 10.1007/s00213-008-1104-0. Epub 2008 Apr 30. Erratum in: Psychopharmacology (Berl). 2011 Jul;216(1):151.

PMID:
18446329
4.

The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition.

Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, Piomelli D, Mikics E, Haller J, Yasar S, Tanda G, Goldberg SR.

Neuropharmacology. 2008 Jan;54(1):129-40. Epub 2007 Aug 19.

5.

FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.

Falenski KW, Thorpe AJ, Schlosburg JE, Cravatt BF, Abdullah RA, Smith TH, Selley DE, Lichtman AH, Sim-Selley LJ.

Neuropsychopharmacology. 2010 Jul;35(8):1775-87. doi: 10.1038/npp.2010.44. Epub 2010 Mar 31.

6.

The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport.

Solinas M, Tanda G, Justinova Z, Wertheim CE, Yasar S, Piomelli D, Vadivel SK, Makriyannis A, Goldberg SR.

J Pharmacol Exp Ther. 2007 Apr;321(1):370-80. Epub 2007 Jan 8.

7.

Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.

Walentiny DM, Vann RE, Wiley JL.

Neuropharmacology. 2015 Jun;93:237-42. doi: 10.1016/j.neuropharm.2015.02.004. Epub 2015 Feb 16.

8.

Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.

Haller VL, Stevens DL, Welch SP.

Eur J Pharmacol. 2008 Dec 14;600(1-3):50-8. doi: 10.1016/j.ejphar.2008.08.005. Epub 2008 Aug 20.

PMID:
18762181
9.
10.

Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates.

Kangas BD, Leonard MZ, Shukla VG, Alapafuja SO, Nikas SP, Makriyannis A, Bergman J.

J Pharmacol Exp Ther. 2016 Apr;357(1):125-33. doi: 10.1124/jpet.115.228189. Epub 2016 Jan 29.

11.

Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist.

Justinová Z, Ferré S, Redhi GH, Mascia P, Stroik J, Quarta D, Yasar S, Müller CE, Franco R, Goldberg SR.

Addict Biol. 2011 Jul;16(3):405-15. doi: 10.1111/j.1369-1600.2010.00258.x. Epub 2010 Nov 4.

14.

Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.

Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D.

J Pharmacol Exp Ther. 2005 Apr;313(1):352-8. Epub 2004 Dec 3.

15.

Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats.

Scherma M, Panlilio LV, Fadda P, Fattore L, Gamaleddin I, Le Foll B, Justinová Z, Mikics E, Haller J, Medalie J, Stroik J, Barnes C, Yasar S, Tanda G, Piomelli D, Fratta W, Goldberg SR.

J Pharmacol Exp Ther. 2008 Nov;327(2):482-90. doi: 10.1124/jpet.108.142224. Epub 2008 Aug 25. Erratum in: J Pharmacol Exp Ther. 2011 Jun;337(3):887.

16.

Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents.

Wiley JL, Walentiny DM, Wright MJ Jr, Beardsley PM, Burston JJ, Poklis JL, Lichtman AH, Vann RE.

Eur J Pharmacol. 2014 Aug 15;737:97-105. doi: 10.1016/j.ejphar.2014.05.013. Epub 2014 May 22.

17.

Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats.

Kwilasz AJ, Abdullah RA, Poklis JL, Lichtman AH, Negus SS.

Behav Pharmacol. 2014 Apr;25(2):119-29. doi: 10.1097/FBP.0000000000000023.

18.
19.

Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse.

Justinova Z, Panlilio LV, Moreno-Sanz G, Redhi GH, Auber A, Secci ME, Mascia P, Bandiera T, Armirotti A, Bertorelli R, Chefer SI, Barnes C, Yasar S, Piomelli D, Goldberg SR.

Neuropsychopharmacology. 2015 Aug;40(9):2185-97. doi: 10.1038/npp.2015.62. Epub 2015 Mar 10.

20.

Supplemental Content

Support Center